Nutra Pharma Reports ReceptoPharm Assays Prove That Experimental HIV Drug May Be Widely Available after Approval --------------------------------------------------------------------------------
1-Sep-2004
BOYNTON BEACH, Fla.--(BUSINESS WIRE)--Sept. 1, 2004--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced today that its minority-owned holding, ReceptoPharm, Inc., has discovered the potential for widely available cobra venoms as a raw material in the development of a treatment for HIV and possibly AIDS. This is a significant discovery as cobras are indigenous where HIV infection is rampant. Cobra venom from different geographical locations has been assayed for effectiveness in inhibiting HIV replication. Venoms from cobras found in Africa and Asia have demonstrated antiviral activity. "This permits the use of diverse venom sources to produce the drug in a cost-effective way and meet the requirements of the millions in need of treatment," commented Paul Reid, PhD, CEO of ReceptoPharm. "The production of cobra venom for use in antisera manufacturing is well established and could be scaled-up to meet the demands for anti-retroviral therapy. Tens if not hundreds of kilograms of venoms are produced globally and the Company believes that one kilogram could provide as many as one million doses. Our recent efforts in cloning one of the active components should increase drug supply," he concluded.
The key now to a promising new drug is its ability to block emerging drug-resistant HIV strains. The Company is examining this aspect in independent laboratories and feels confident that this should not be a problem. Preliminary research suggests the anti-viral mechanism is independent of current treatment methods. The venom's complexity should also make it more resilient to the development of resistant viral strains.
"The drug already has a well established history in humans so we believe that clinical studies should commence quickly," stated Rik Deitsch, Nutra Pharma's CEO. "By showing that there is a ready supply of natural raw material, ReceptoPharm may be able to quickly supply the drug to patients in the geographic areas most desperate for cost-effective treatment," he added.
ReceptoPharm recently moved into a larger facility and expects to move quickly into GMP production. The Company has near-term requirements for drug supplies to meet clinical trial demands and non-clinical studies. Raw material suppliers in the U.S. have been validated and sufficient venom supplies are available for the current clinical program and early commercialization.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biotechnology holding company that owns rights to patents and intellectual property related to the development of drugs for HIV and Multiple Sclerosis ("MS"). The Company's minority-owned holding, ReceptoPharm, Inc., is developing these technologies. The Company's majority-owned subsidiary, Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma will continue to identify and acquire intellectual property and companies in the biotechnology arena. http://www.nutrapharma.com
About ReceptoPharm
ReceptoPharm, Inc. is a bio-pharmaceutical company developing proprietary therapeutic proteins for the treatment of several chronic, life-threatening viral, auto-immune and neuro-degenerative disorders, specifically including Rabies, HIV, and Myasthenia gravis (MG).
Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including, but not limited to, risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission. Nothing in this press release shall be construed as an offer to buy or sell any securities herein.
posted
this is really great news. some of the major problems with companies that get an hiv drug is not having the ability to produce enough therefore limiting sales.
posted
also had a chance to listen to the ceocast.com interview with nutrapharma ceo. i encourage all to check it out.
quote:Originally posted by thebigpoppa: this is really great news. some of the major problems with companies that get an hiv drug is not having the ability to produce enough therefore limiting sales.
posted
nutrapharma expects to have results from hiv study around end of forst qtr 2005.
quote:Originally posted by thebigpoppa: also had a chance to listen to the ceocast.com interview with nutrapharma ceo. i encourage all to check it out.
quote:Originally posted by thebigpoppa: nutrapharma expects to have results from hiv study around end of forst qtr 2005.
I AM highly confused, I have been watching this stock for a week now and the VOLUME TODAY WAS 500 SHARES. I just dont understand the sex appeal of this stock, no one knows about it and you guys say it could go up to $20.00, please explain?
posted
Does anybody know what is going on with the stock NPHC? This stock has tanked alot this last year. thebigpoppa was wrong on everything he said and now we haven't heard from him in 1 year. If anybody has an opinion on this company, please share it with the rest of us.
Posts: 4 | Registered: Oct 2005
| IP: Logged |
posted
This message is for tfct24 or anyone who has been watching the stock NPHC. Does anyone think this company has potential? There website is www.nutrapharma.com According to there news they have and HIV drug, MS drug, and a AMN drug that may work. But the problem is they have been saying for the last 2 years that there going to begin human trials and they haven't began anything. It seems very misleading to me, but what due I know. The only thinh I know is the stock is 20 cents per share and they have no trading volume. Please give me your thoughts if possible.
Posts: 4 | Registered: Oct 2005
| IP: Logged |
posted
I have did some research on Nutra Pharma Corporation. I think it is only a matter of time before this company moves to the next level. it looks like by years end or first part of 2006 they will access to roughly $10MM. If this drug works like the beginning tests have stated on the past news and continues to show positive results, this could be a huge gain from there current price.
Posts: 4 | Registered: Oct 2005
| IP: Logged |
posted
Hey all -- NPHC has gone up and way down since I originally posted...I'm still really high on this company because its pipeline is so good. The deal they signed with SBI will put them on the map. I blieve they are just waiting for the shares to be registered with the SEC...between SBI and this other company in China (you know - the one that is being paid in $0.70 warrants!!), Nutra Pharma shares only have one way to go -- and that is UP! I believe they were waiting for the additional capital to begin the phase III trials -- someone else might know the answer to this, but don't most of these companies have the big pharma companies come in to license at Phase III? Good luck to all -- FYI, I avg'd down when the stock was low.
Posts: 91 | Registered: Oct 2004
| IP: Logged |
posted
Anyone else following this company still? I always check out their website to see what information they posted...it doesnt make any sense why the company is so undervalued...any thoughts?
Posts: 91 | Registered: Oct 2004
| IP: Logged |
posted
After doing my homework on Nutra Pharma Corporation I have found the following. They have diluted there stock alot over the last 2 years. They have to raise money on an ongoing basis. This drug has been around for 15 years and has yet to make it to the market. I think it could have huge potential but looks like a long shot when you look at the overall picture. The stock has been trading at all time lows between 11-15 cents.
Posts: 4 | Registered: Oct 2005
| IP: Logged |
posted
Just pulled this -- Nutra Pharma Corp. (OTC BB:NPHC.OB), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that it has been accepted into the Stop TB Partnership. Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma has also been accepted into the organization.
full press release is on their site (http://www.nutrapharma.com) -- this helps legitimize the company...
Posts: 91 | Registered: Oct 2004
| IP: Logged |